Gary Goldenberg - 01 Mar 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Medical Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 15:26:41 UTC
Previous filing
05 Jul 2022
Next filing
25 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Employee Stock Option (right to buy) Award $0 +85,000 $0.000000 85,000 01 Mar 2023 Common Stock 85,000 $7.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.